| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/(SICI)1097-0215(20000320)89:2<160::AID-IJC10>3.0.CO;2-J |
| P698 | PubMed publication ID | 10754494 |
| P2093 | author name string | D Majoor | |
| D de Jong | |||
| A C Begg | |||
| H Bartelink | |||
| K C Sneeuw | |||
| P J van de Vaart | |||
| J Belderbos | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cisplatin | Q412415 |
| non-small-cell lung carcinoma | Q3658562 | ||
| P304 | page(s) | 160-166 | |
| P577 | publication date | 2000-03-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy | |
| P478 | volume | 89 |
| Q38706298 | A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. |
| Q35131936 | A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance |
| Q36430311 | Applications of genomics in NSCLC. |
| Q36615096 | Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development. |
| Q31106049 | Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy |
| Q44730628 | Bloodstream form-specific up-regulation of silent vsg expression sites and procyclin in Trypanosoma brucei after inhibition of DNA synthesis or DNA damage. |
| Q38669287 | Chemotherapy Resistance in Lung Cancer |
| Q42144353 | Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor |
| Q34348474 | Cisplatin: from DNA damage to cancer chemotherapy. |
| Q82734638 | Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status |
| Q77828166 | Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial |
| Q73313314 | Concurrent chemotherapy and radiation for locally advanced squamous cell cancers: what is the schedule of choice? |
| Q58079341 | Correlation of platinum cytotoxicity to drug-DNA adduct levels in a breast cancer cell line panel |
| Q37736567 | DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. |
| Q39922287 | DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response |
| Q38287679 | DNA bending and unwinding due to the major 1,2-GG intrastrand cross-link formed by antitumor cis-diamminedichloroplatinum(II) are flanking-base independent |
| Q44876602 | ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy |
| Q34694410 | ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis |
| Q36755127 | ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation |
| Q46486164 | ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy |
| Q36615632 | ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen |
| Q90355627 | Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin |
| Q48370483 | From translational research to improved local control and survival: the Gilbert Fletcher Award Lecture, Lugano, March 2000. |
| Q34328748 | Gemcitabine Causes Minimal Modulation of Carboplatin-DNA Monoadduct Formation and Repair in Bladder Cancer Cells |
| Q35179434 | Genetic testing for chemotherapy in non-small cell lung cancer |
| Q36291188 | Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo |
| Q35770249 | Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation |
| Q80845931 | Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer |
| Q61182985 | Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial |
| Q30657753 | Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies |
| Q35951523 | Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis |
| Q39947163 | Kinetics of H2AX phosphorylation after exposure to cisplatin |
| Q38728212 | Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice |
| Q35957598 | Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer. |
| Q34866688 | Molecular aspects of resistance to antitumor platinum drugs. |
| Q36817080 | Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer |
| Q36597012 | Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer |
| Q35048754 | Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies |
| Q42340129 | Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC. |
| Q35851986 | Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review |
| Q37323814 | Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer |
| Q35779460 | Progress in personalizing chemotherapy for bladder cancer |
| Q33186035 | Quantification of DNA adducts in individual cells by immunofluorescence: effects of variation in DNA conformation |
| Q34629768 | Rates of intercalator-driven platination of DNA determined by a restriction enzyme cleavage inhibition assay |
| Q50947717 | Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy. |
| Q38171397 | The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis |
| Q34501921 | The combined use of radiotherapy and chemotherapy in the treatment of solid tumours |
| Q87659659 | The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer |
| Q28396304 | Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer |
| Q28818313 | Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology |
| Q35015020 | XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer |
Search more.